Development of a novel Zika virus mRNA vaccine and its cross-protection against dengue virus.
By designing peptides and linear mRNAs containing fragments of Zika virus EDIII, E, NS3, and NS5 proteins, T-cell and B-cell immunity were stimulated, solving the ADE effect problem caused by Zika virus vaccines and achieving cross-protection against Zika virus and dengue virus with improved safety.
Patent Information
- Application Number
- CN202610528055.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-04-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing Zika virus (ZIKV) vaccines may induce clinical risks of dengue virus (DENV) infection after vaccination. The antibody-dependent enhancement effect (ADE) mediated by Fcγ receptor increases the risk of dengue hemorrhagic fever and dengue shock syndrome. There is an urgent need to develop flavivirus vaccines that can eliminate the ADE effect and prevent ZIKV and DENV infection.
Design a polypeptide and linear mRNA containing fragments of Zika virus EDIII, E, NS3, and NS5 proteins, linked by sequences encoding linkers or located in different mRNA molecules, to stimulate T-cell immunity and B-cell-mediated humoral immunity while avoiding toxic side effects.
It effectively activates animal cell-mediated immune responses, improves safety, reduces side effects, achieves cross-protection against Zika virus and dengue virus, and reduces the clinical risks caused by ADE effects.
Smart Images

Figure CN123106918A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, specifically to the development of a novel Zika virus mRNA vaccine and its cross-protective application against dengue virus, and more specifically to a polypeptide, linear mRNA, isolated nucleic acid molecule, expression vector, recombinant virus, composition, vaccine, recombinant cell, method for constructing a Zika virus vaccine, and its uses. Background Technology
[0002] Cross-reactivity between Zika virus (ZIKV), a member of the Flaviviridae family of the genus Flaviviridae, and dengue virus (DENV) remains unresolved. Primary immunization with ZIKV induces a specific humoral immune response and forms a pool of memory B cells. However, during secondary DENV infection, non-neutralizing antibodies induced by the ZIKV vaccine may lead to increased viral endocytosis and viral load amplification through Fcγ receptor-mediated antibody-dependent enhancement (ADE), significantly increasing the clinical risk of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Therefore, there is an urgent need to develop flavivirus vaccines that can eliminate the ADE effect and simultaneously prevent both ZIKV and DENV infections. Summary of the Invention
[0003] This application is made by the inventors based on their findings regarding the following problems and facts: In recent years, the greenhouse effect has led to the rampant proliferation of vector-borne diseases, making the transmission dynamics of vector-borne infectious diseases increasingly complex. The co-circulation of different viruses in the same time and space poses a significant threat to public health. Furthermore, non-neutralizing antibodies can affect the host's immune response through multiple mechanisms, and the ADE effect is a key challenge in flavivirus vaccine development. To overcome this problem, this application develops a flavivirus vaccine that can eliminate ADE without affecting immunogenicity.
[0004] Based on this, in one aspect of this application, a polypeptide is proposed. According to an embodiment of this application, the polypeptide comprises a first polypeptide fragment comprising an EDIII protein fragment of Zika virus; a second polypeptide fragment comprising at least one of an E protein fragment, an NS3 protein fragment, and an NS5 protein fragment of Zika virus; the first polypeptide fragment and the second polypeptide fragment may be linked or not linked. The polypeptide according to the embodiment of this application exhibits strong immunogenicity and few side effects.
[0005] In another aspect of this application, a linear mRNA is proposed. According to embodiments of this application, the linear mRNA comprises: a nucleic acid fragment encoding the aforementioned polypeptide, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encoding the EDIII protein fragment of Zika virus; the second nucleic acid fragment encoding at least one of the E protein fragment, NS3 protein fragment, and NS5 protein fragment of Zika virus; the first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different linear mRNA molecules. According to embodiments of the present invention, a linear mRNA expressing any one or a combination of the EDIII and E protein fragments, NS3 and NS5 protein fragments of Zika virus can stimulate T cell immunity and B cell-mediated humoral immunity.
[0006] In another aspect of this application, an isolated nucleic acid molecule is provided. According to an embodiment of this application, the isolated nucleic acid molecule encodes the aforementioned polypeptide, and the nucleic acid molecule is mRNA; the isolated nucleic acid molecule comprises: a first nucleic acid fragment encoding a Zika virus EDIII protein fragment; and a second nucleic acid fragment encoding at least one of a Zika virus E protein fragment, NS3 protein fragment, and NS5 protein fragment; the first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different mRNA molecules. According to embodiments of the present invention, a nucleic acid molecule expressing at least one of the Zika virus EDIII protein fragment and C3d protein fragment, E protein fragment, NS3 protein fragment, and NS5 protein fragment can stimulate T cell immunity and B cell-mediated humoral immunity.
[0007] In another aspect of this application, an expression vector is provided. According to embodiments of this application, the expression vector carries the aforementioned nucleic acid molecule. According to embodiments of the invention, the expression vector can be expressed in cells, bacteria, yeast, or feline organisms.
[0008] In another aspect of this application, a vaccine is proposed. According to embodiments of this application, the vaccine comprises the aforementioned polypeptide, the aforementioned linear mRNA, the aforementioned nucleic acid molecule, or the aforementioned expression vector. The vaccine according to embodiments of the present invention can efficiently activate animal cell-mediated immune responses. Furthermore, the vaccine contains only protein fragments capable of activating cellular immune responses, avoiding toxic side effects and exhibiting higher safety.
[0009] In another aspect of this application, a recombinant cell is provided. According to embodiments of this application, the recombinant cell carries the aforementioned linear mRNA, the aforementioned nucleic acid molecule, the aforementioned expression vector, or expresses the aforementioned polypeptide.
[0010] In another aspect of this application, a method for preparing the aforementioned linear mRNA is provided. According to an embodiment of this application, the method includes: mixing a first nucleic acid fragment and a second nucleic acid fragment in a predetermined ratio to obtain the linear mRNA; wherein the first nucleic acid fragment encodes the EDIII protein fragment of Zika virus; the second nucleic acid fragment encodes at least one of the E protein fragment, NS3 protein fragment, and NS5 protein fragment of Zika virus; and the first and second nucleic acid fragments are mRNA. According to an embodiment of this application, this method can be used to prepare linear mRNA for the prevention or treatment of diseases caused by Zika virus.
[0011] In another aspect of this application, a method for constructing a Zika virus vaccine is provided. According to embodiments of this application, the method includes: introducing the aforementioned linear mRNA, the aforementioned nucleic acid molecule, or the aforementioned expression vector into recipient cells. The method according to embodiments of the present invention can be used to prepare nucleic acid vaccines. The method for constructing a Zika virus vaccine is safe, simple, and efficient.
[0012] In another aspect of this application, a composition is provided. According to embodiments of this application, the composition comprises the aforementioned polypeptide, the aforementioned linear mRNA, the aforementioned nucleic acid molecule, or the aforementioned vaccine.
[0013] In another aspect of this application, the use of the aforementioned polypeptide, linear mRNA, nucleic acid molecule, expression vector, vaccine, or composition in the preparation of a medicament for the prevention or treatment of Zika virus infection-related diseases is provided. According to embodiments of the present invention, medicaments prepared based on the aforementioned linear mRNA, nucleic acid molecule, expression vector, vaccine, or composition exhibit high safety and can rapidly activate animal cell-mediated immune responses.
[0014] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description
[0015] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which: Figure 1 This is a schematic diagram of the dual antigen vaccine design in Example 1.
[0016] Figure 2 It is UbA-EDIII in Example 2 C3d Physicochemical properties diagram of the vaccine.
[0017] Figure 3 It is EDIII in Example 3 C3d The results of Western blot analysis of transfected cells are shown in the figure.
[0018] Figure 4 This is a diagram illustrating the in vitro functional verification of UbA-transfected cells in Example 4.
[0019] Figure 5 It is UbA EDIII and EDIII in Example 5 C3d Figure showing the in vivo functional comparison and validation of mRNA vaccines.
[0020] Figure 6 This is a schematic diagram of the cross-protective response experiment of ZIKV and DENV2 viruses in immunodeficient mice in Example 6.
[0021] Figure 7 In Example 7, ZIKV and DENV2 are... Infar1 – / – Ifngr1 – / – Verification diagram of cross-immune response in mice.
[0022] Figure 8 In Example 8, mice immunized with the ZIKV antigen peptide produced memory CD8. + Diagram illustrating the inhibitory effect of T cells on DENV2 infection.
[0023] Figure 9 It is UbA-EDIIIC in Example 9 3d Vaccine antibody type verification diagram.
[0024] Figure 10 It is UbA-EDIIIC in Example 10 3d A diagram showing the reaction during hair regrowth stimulated by a vaccine.
[0025] Figure 11 This is a graph of the T-cell response in mice induced by the dual immunization vaccine in Example 11 on day 42.
[0026] Figure 12 It is UbA-EDIIIC in Example 12 3d A diagram illustrating the vaccine's induction of neutralization and its protective efficacy.
[0027] Figure 13 It is UbA-EDIII in Example 13 C3d Graph showing the detection and analysis of viral load and memory antibodies in vaccine tissue.
[0028] Figure 14 It is UbA-EDIII in Example 14 C3d A diagram of ADE effect detection in vaccines.
[0029] Figure 15 This is a safety test diagram of the mRNA vaccine in Example 15.
[0030] Figure 16 These are images of mRNA serum biochemical and histopathological detection from Example 16. Detailed Implementation
[0031] The embodiments of this application are described in detail below. The embodiments described below are exemplary and are only used to explain this application, and should not be construed as limiting this application.
[0032] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this application, unless otherwise stated, "multiple" means two or more.
[0033] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.
[0034] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.
[0035] In this paper, the term "fragment" refers to a partial nucleic acid fragment having a 5' end and a 3' end, or a partial protein fragment having an N-terminus and a C-terminus.
[0036] In this paper, the term "at least 90% identity" means at least 90% identity with each reference sequence, which may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%.
[0037] In this document, unless otherwise specified, "identity" is used to describe the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences relative to a reference sequence, determined by conventional methods such as NCBI Blast v2.0, to calculate the degree of sequence identity between two or more nucleotide sequences. Other techniques, computer algorithms, and settings used to determine the degree of sequence identity are referenced in WO 04 / 037999, EP 0967 284, EP 1 085 089, WO 00 / 55318, WO 00 / 78972, WO 98 / 49185, and GB 2357768-A.
[0038] In this document, the term "expression vector" generally refers to a nucleic acid molecule capable of self-replication within a suitable host, transferring the inserted nucleic acid molecule to host cells and / or between host cells. The expression vector may include vectors primarily for inserting DNA or RNA into cells, vectors primarily for replicating DNA or RNA, and expression vectors primarily for transcription and / or translation of DNA or RNA. The expression vector also includes vectors having multiple of the aforementioned functions. The expression vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, by culturing suitable host cells containing the expression vector, the expression vector can produce the desired expression product.
[0039] In this document, the term "recombinant cell" generally refers to a cell in which the genetic material of a host cell is modified or recombined using genetic engineering or cell fusion techniques to obtain a unique trait with stable inheritance. The term "host cell" refers to a prokaryotic or eukaryotic cell into which a recombinant expression vector can be introduced. The terms "transformed" or "transfected" as used herein refer to the introduction of nucleic acids (e.g., vectors) into cells using various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequences of this invention and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used in this invention include immortalized hybridoma cells, NS / O myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid), and CoS cells.
[0040] In this document, the term "vaccine" is understood to refer to a linear mRNA with immune activity. In some embodiments, a vaccine induces adaptive immunity upon administration to a host. Vaccine formulations may also contain pharmaceutically acceptable excipients that may be engineered for a specific mode of administration intended for the purpose of administering the vaccine.
[0041] In this document, the term "pharmaceutical acceptable" means that the composition must be chemically and / or toxicologically compatible with other components comprising the formulation and / or the mammals to which it is treated. Preferably, "pharmaceutical acceptable" as used herein means approved by a federal regulatory agency or national government, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeia for use in animals, particularly in humans.
[0042] In this document, the term "pharmaceuticalally acceptable excipient" may include any solvent, stabilizer, diluent, or other liquid excipient, etc., suitable for the specific target dosage form. The use of any conventional excipients, except for those incompatible with the vaccine of this application, such as any adverse biological effects or harmful interactions with any other component of the pharmaceutically acceptable composition, is also within the scope of this application.
[0043] In this document, the term "treatment" refers to the use of a drug to achieve a desired pharmacological and / or physiological effect. This effect may be preventative in terms of complete or partial prevention of a disease or its symptoms, and / or therapeutic in terms of partial or complete cure of a disease and / or adverse effects caused by the disease. As used herein, "treatment" encompasses diseases in mammals, particularly humans, including: (a) prevention of disease or the onset of a disease in individuals who are susceptible but have not yet been diagnosed with the disease; (b) suppression of disease, such as inhibiting disease progression; or (c) alleviating disease, such as reducing disease-related symptoms. As used herein, "treatment" encompasses any medication that administers a vaccine to an individual to treat, cure, alleviate, improve, reduce, or suppress the individual's disease, including but not limited to administering a vaccine containing the vaccine described herein to an individual in need.
[0044] In this document, the term "administration" refers to the introduction of a predetermined amount of a substance into a patient in a suitable manner. The vaccine of this application can be administered via any common route, as long as it can reach the intended tissue. Various routes of administration are foreseeable, including peritoneal, intravenous, intramuscular, subcutaneous, etc., but this application is not limited to these exemplified routes of administration. Preferably, the vaccine or pharmaceutical composition of this application is administered via intravenous or subcutaneous injection.
[0045] This invention proposes a polypeptide, linear mRNA, a method for preparing linear mRNA, isolated nucleic acid molecules, expression vectors, compositions, vaccines, recombinant cells, a method for constructing a Zika virus vaccine, and their uses, which will be described in detail below.
[0046] polypeptide In one aspect of this application, a polypeptide is provided. According to an embodiment of this application, the polypeptide comprises a first polypeptide fragment comprising an EDIII protein fragment of Zika virus; a second polypeptide fragment comprising at least one of an E protein fragment, an NS3 protein fragment, and an NS5 protein fragment of Zika virus; the first polypeptide fragment and the second polypeptide fragment may be linked or not linked. The polypeptide according to the embodiment of this application exhibits strong immunogenicity and few side effects.
[0047] According to embodiments of this application, the polypeptide comprises a first polypeptide fragment, which includes a Zika virus EDIII protein fragment and 1 to 10 tandemly repeated Zika virus complement C3d protein fragments; and a second polypeptide fragment, which includes at least one of a Zika virus E protein fragment, an NS3 protein fragment, and an NS5 protein fragment; the first polypeptide fragment and the second polypeptide fragment may be linked or not linked. The polypeptides according to embodiments of this application exhibit strong immunogenicity and few side effects. It should be noted that, as used herein, "protein fragment" refers to at least a portion of the full-length amino acid sequence of a protein; for example, "EDIII protein fragment" refers to at least a portion of the full-length EDIII protein sequence; "C3d protein fragment" refers to at least a portion of the full-length C3d protein sequence; "E protein fragment" refers to at least a portion of the full-length E protein sequence; "NS3 protein fragment" refers to at least a portion of the full-length NS3 protein sequence; and "NS5 protein fragment" refers to at least a portion of the full-length NS5 protein sequence.
[0048] According to an embodiment of this application, the first polypeptide fragment and the second polypeptide fragment are not linked.
[0049] According to embodiments of this application, the second polypeptide fragment further includes a ubiquitinated monomer fragment.
[0050] According to an embodiment of this application, the ubiquitinated monomer fragment has a G76A mutation.
[0051] According to the embodiments of this application, the number of C3d protein fragments is 1 to 5, for example, 1, 2, 3, 4, or 5.
[0052] According to an embodiment of this application, the C-terminus of the EDIII protein fragment is connected to the N-terminus of the first C3d protein fragment, the C-terminus of the first C3d protein fragment is connected to the N-terminus of the second C3d protein fragment, and the C-terminus of the second C3d protein fragment is connected to the N-terminus of the third C3d protein fragment.
[0053] According to an embodiment of this application, the C-terminus of the ubiquitinated monomer fragment is connected to the N-terminus of the E protein fragment, the C-terminus of the E protein fragment is connected to the N-terminus of the NS3 protein fragment, and the C-terminus of the NS3 protein fragment is connected to the N-terminus of the NS5 protein fragment.
[0054] According to embodiments of this application, the second polypeptide fragment further comprises a linker peptide.
[0055] According to embodiments of this application, the linker peptide includes a first linker peptide, a second linker peptide, a third linker peptide, a fourth linker peptide, a fifth linker peptide, and a sixth linker peptide.
[0056] According to an embodiment of this application, the first linker peptide is disposed between the ubiquitinated monomer fragment and the E protein fragment, the second and third linker peptides are disposed between the E protein fragment and the NS3 protein fragment, and the fourth and fifth linker peptides are disposed between the NS3 protein fragment and the NS5 protein fragment.
[0057] According to an embodiment of this application, the C-terminus of the ubiquitinated monomer fragment is connected to the N-terminus of the first linker peptide, the C-terminus of the first linker peptide is connected to the N-terminus of the E protein fragment, the C-terminus of the E protein fragment is connected to the N-terminus of the second linker peptide, the C-terminus of the second linker peptide is connected to the N-terminus of the third linker peptide, the C-terminus of the third linker peptide is connected to the N-terminus of the NS3 protein fragment, the C-terminus of the NS3 protein fragment is connected to the N-terminus of the fourth linker peptide, the C-terminus of the fourth linker peptide is connected to the N-terminus of the fifth linker peptide, and the C-terminus of the fifth linker peptide is connected to the N-terminus of the NS5 protein fragment.
[0058] linear mRNA In another aspect of this application, a linear mRNA is proposed. According to embodiments of this application, the linear mRNA comprises: a nucleic acid fragment encoding the aforementioned polypeptide, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encoding the EDIII protein fragment of Zika virus; the second nucleic acid fragment encoding at least one of the E protein fragment, NS3 protein fragment, and NS5 protein fragment of Zika virus; the first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different linear mRNA molecules. According to embodiments of the present invention, a linear mRNA expressing any one or a combination of the EDIII and E protein fragments, NS3 and NS5 protein fragments of Zika virus can stimulate T cell immunity and B cell-mediated humoral immunity.
[0059] According to embodiments of this application, the linear mRNA comprises: a nucleic acid fragment encoding the aforementioned polypeptide, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encoding the Zika virus EDIII protein fragment and 1 to 10 tandemly repeated Zika virus complement C3d protein fragments; the second nucleic acid fragment encoding at least one of the Zika virus E protein fragment, NS3 protein fragment, and NS5 protein fragment; the first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different linear mRNA molecules. According to embodiments of the present invention, linear mRNA expressing any one or a combination of the Zika virus EDIII and E protein fragments, NS3 and NS5 protein fragments can stimulate T cell immunity and B cell-mediated humoral immunity.
[0060] According to embodiments of this application, the first nucleic acid fragment and the second nucleic acid fragment are located in different linear mRNA molecules.
[0061] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(1~50).
[0062] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(3~10).
[0063] According to an embodiment of this application, the second nucleic acid fragment further includes at least one of encoding a T7 promoter, a 5'UTR, a Kozak sequence, a ubiquitinated monomer, a linker, a V5 tag, a 3'UTR, and a polyA tail.
[0064] According to an embodiment of this application, the first nucleic acid fragment further includes at least one of encoding the T7 promoter, 5'UTR, Kozak sequence, His tag, 3'UTR, and polyA tail.
[0065] According to embodiments of this application, the linker is 25-35 nucleotides in length, for example, it can be 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or a range between 26-35 nucleotides or 27-35 nucleotides. It should be noted that, in order to preserve the CTL epitope, this application extends the linker by 25-35 nucleotides before and after each cleavage site, i.e., the linker in this application.
[0066] According to embodiments of this application, the length of the polyA tail is 110 to 140 nucleotides, for example, it can be 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 125, 130, 135, 140 nucleotides or a range between the two, 111 to 140 nucleotides or 112 to 140 nucleotides.
[0067] According to embodiments of this application, the connector includes a first connector, a second connector, a third connector, a fourth connector, a fifth connector, and a sixth connector.
[0068] According to an embodiment of this application, the nucleotide sequence of the first linker is shown in SEQ ID NO: 8.
[0069] ccggcgtatagcattcgctgcattggcgtg (SEQ ID NO: 8) According to an embodiment of this application, the nucleotide sequence of the second linker is shown in SEQ ID NO: 9.
[0070] agcggcggcacctgggtggatgtggtgctg (SEQ ID NO: 9) According to an embodiment of this application, the nucleotide sequence of the third linker is shown in SEQ ID NO: 10.
[0071] gatcatagcggcaaaaccgtgtggtttgtg (SEQ ID NO: 10) According to an embodiment of this application, the nucleotide sequence of the fourth linker is shown in SEQ ID NO: 11.
[0072] gcggcgtgcctgaccaaagcgggcaaacgc (SEQ ID NO: 11) According to an embodiment of this application, the nucleotide sequence of the fifth linker is shown in SEQ ID NO: 12.
[0073] ctgggcagcggcacccgcgcggtggtgagc (SEQ ID NO: 12) According to an embodiment of this application, the nucleotide sequence of the sixth linker is shown in SEQ ID NO: 13.
[0074] ggcaaccgcattgaacgcattcgcagcgaa (SEQ ID NO: 13) According to an embodiment of this application, the nucleotide sequence of the T7 promoter is shown in SEQ ID NO: 14.
[0075] TAATACGACTCACTATAGG (SEQ ID NO: 14) According to an embodiment of this application, the nucleotide sequence of the 5'UTR is shown in SEQ ID NO: 15.
[0076] GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ ID NO: 15) According to an embodiment of this application, the nucleotide sequence of the Kozak sequence is shown in SEQ ID NO: 16.
[0077] GCCACC (SEQ ID NO: 16) According to an embodiment of this application, the nucleotide sequence of the ubiquitinated monomer is shown in SEQ ID NO: 17.
[0078] ATGCAGATTTTCGTGAAAACCCTGACCGGGAAAACCATCACCCTGGAAGTCGAGCCCAGCGACACCATCGAGAACGTCAAGGCCAAAATCCAGGACAAGGAGGGCATCCCCCCGACCAGCAGAGGCTGATCTTCGCCGGCAAGCAGCTGGAAGACGGCAGAACACTGAGCGACTACAACATCCAGAAGGAAAGCACCCTGCACCTGGTGCTGAGACTGAGAGGCGCC (SEQ ID NO: 17) According to an embodiment of this application, the nucleotide sequence of the V5 tag is shown in SEQ ID NO: 18.
[0079] GCGGCGTATGGCAAACCGATTCCGAACCCGCTGCTGGGCCTGGATAGCACC (SEQ ID NO: 18) According to an embodiment of this application, the nucleotide sequence of the 3'UTR is shown in SEQ ID NO: 19.
[0080] TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAAGTCTGAGTATAC (SEQ ID NO: 19) According to an embodiment of this application, the linking sequence of the second nucleic acid fragment is as follows: the 3' end of the T7 promoter is linked to the 5' end of the 5' UTR; the 3' end of the 5' UTR is linked to the 5' end of the Kozak sequence; the 3' end of the Kozak sequence is linked to the 3' end of the ubiquitinated monomer; the 3' end of the ubiquitinated monomer is linked to the 5' end of the first linker; the 3' end of the first linker is linked to the 5' end of the E protein fragment; the 3' end of the E protein fragment is linked to the 5' end of the second linker; the 3' end of the second linker is linked to the 5' end of the third linker; the 3' end of the third linker is linked to the 5' end of the NS3 protein fragment; the 3' end of the NS3 protein fragment is linked to the 5' end of the fourth linker; the 3' end of the fourth linker is linked to the 5' end of the fifth linker; the 3' end of the fifth linker is linked to the 5' end of the NS5 protein fragment; the 3' end of the NS5 protein fragment is linked to the 5' end of the sixth linker; and the 3' end of the sixth linker is linked to the V5... The 5' end of the tag is connected, the 3' end of the V5 tag is connected to the 5' end of the 3'UTR, and the 3' end of the 3'UTR is connected to the 5' end of the polyA tail.
[0081] According to an embodiment of this application, the linking sequence of the first nucleic acid fragment is as follows: the 3' end of the T7 promoter is linked to the 5' end of the 5'UTR; the 3' end of the 5'UTR is linked to the 5' end of the Kozak sequence; the 3' end of the Kozak sequence is linked to the 5' end of the EDIII protein fragment; the 3' end of the EDIII protein fragment is linked to the 5' end of the C3d protein fragment; the 3' end of the C3d protein fragment is linked to the 5' end of the His tag; the 3' end of the His tag is linked to the 5' end of the 3'UTR; and the 3' end of the 3'UTR is linked to the 5' end of the polyA tail.
[0082] According to embodiments of this application, the EDIII protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 1.
[0083] Ggcgtgagctatagcctgtgcaccgcggcgtttacctttaccaaaattccggcggaaaccctgcatggcaccgtgaccgtggaagtgcagtatgcgggcaccgatggcccgtgcaaagtgccggcgcagatggcggtggatatgcagaccctgac cccggtgggccgcctgattaccgcgaacccggtgattaccgaaagcaccgaaaacagcaaaatgatgctggaactggatccgccgtttggcgatagctatattgtgattggcgtgggcgaaaaaaaaattacccatcattggcatcgcagc (seq ID NO: 1) According to embodiments of this application, the C3d protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 2.
[0084] According to embodiments of this application, the E protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 3.
[0085] agcaaccgcgattttgtggaaggcatg (SEQ ID NO: 3) According to embodiments of this application, the NS3 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 4.
[0086] ccgagcgtgcgcaacggcaacgaaatt (SEQ ID NO: 4) According to embodiments of this application, the NS5 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 5.
[0087] tgcgcggaagcgccgaacatgaaaattatt (SEQ ID NO: 5) According to an embodiment of this application, the first nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 6.
[0088] According to an embodiment of this application, the second nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 7.
[0089] According to embodiments of this application, the full-length ZIKV E protein has an amino acid sequence as shown in SEQ ID NO: 20 or an amino acid sequence having at least 90% identity with it.
[0090] IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGLFGKGSLVTCAKFACSKKMTG KSIQPENLEYRImLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMmLELDPP FGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA (SEQ ID NO: 20) isolated nucleic acid molecules In another aspect of this application, an isolated nucleic acid molecule is provided. According to an embodiment of this application, the isolated nucleic acid molecule encodes the aforementioned polypeptide, and the nucleic acid molecule is mRNA; the isolated nucleic acid molecule comprises: a first nucleic acid fragment encoding a Zika virus EDIII protein fragment; and a second nucleic acid fragment encoding at least one of a Zika virus E protein fragment, NS3 protein fragment, and NS5 protein fragment; the first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different mRNA molecules. According to embodiments of the present invention, a nucleic acid molecule expressing at least one of the Zika virus EDIII protein fragment and C3d protein fragment, E protein fragment, NS3 protein fragment, and NS5 protein fragment can stimulate T cell immunity and B cell-mediated humoral immunity.
[0091] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(1~50).
[0092] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(3~10), for example, it can be 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or a range of 1:(3~9) or 1:(3~8).
[0093] According to an embodiment of this application, the second nucleic acid fragment further includes at least one of encoding a T7 promoter, a 5'UTR, a Kozak sequence, a ubiquitinated monomer, a linker, a V5 tag, a 3'UTR, and a polyA tail.
[0094] According to an embodiment of this application, the first nucleic acid fragment further includes at least one of encoding the T7 promoter, 5'UTR, Kozak sequence, His tag, 3'UTR, and polyA tail.
[0095] According to an embodiment of this application, the linker is 25 to 35 nucleotides in length.
[0096] According to embodiments of this application, the length of the polyA tail is 110-140 nucleotides.
[0097] According to embodiments of this application, the connector includes a first connector, a second connector, a third connector, a fourth connector, a fifth connector, and a sixth connector.
[0098] According to an embodiment of this application, the nucleic acid sequence of the first linker is translated to generate the aforementioned first linker peptide.
[0099] According to an embodiment of this application, the nucleic acid sequence of the second linker is translated to generate the aforementioned second linker peptide.
[0100] According to an embodiment of this application, the nucleic acid sequence of the third linker is translated to generate the aforementioned third linker peptide.
[0101] According to an embodiment of this application, the nucleic acid sequence of the fourth linker is translated to generate the aforementioned fourth linker peptide.
[0102] According to an embodiment of this application, the nucleic acid sequence of the fifth linker is translated to generate the aforementioned fifth linker peptide.
[0103] According to an embodiment of this application, the nucleic acid sequence of the sixth linker is translated to generate the aforementioned sixth linker peptide.
[0104] According to an embodiment of this application, the nucleotide sequence of the first linker is shown in SEQ ID NO: 8.
[0105] According to an embodiment of this application, the nucleotide sequence of the second linker is shown in SEQ ID NO: 9.
[0106] According to an embodiment of this application, the nucleotide sequence of the third linker is shown in SEQ ID NO: 10.
[0107] According to an embodiment of this application, the nucleotide sequence of the fourth linker is shown in SEQ ID NO: 11.
[0108] According to an embodiment of this application, the nucleotide sequence of the fifth linker is shown in SEQ ID NO: 12.
[0109] According to an embodiment of this application, the nucleotide sequence of the sixth linker is shown in SEQ ID NO: 13.
[0110] According to an embodiment of this application, the nucleotide sequence of the T7 promoter is shown in SEQ ID NO: 14.
[0111] According to an embodiment of this application, the nucleotide sequence of the 5'UTR is shown in SEQ ID NO: 15.
[0112] According to an embodiment of this application, the nucleotide sequence of the Kozak sequence is shown in SEQ ID NO: 16.
[0113] According to an embodiment of this application, the nucleotide sequence of the ubiquitinated monomer is shown in SEQ ID NO: 17.
[0114] According to an embodiment of this application, the nucleotide sequence of the V5 tag is shown in SEQ ID NO: 18.
[0115] According to an embodiment of this application, the nucleotide sequence of the 3'UTR is shown in SEQ ID NO: 19.
[0116] According to an embodiment of this application, the linking sequence of the second nucleic acid fragment is as follows: the 3' end of the T7 promoter is linked to the 5' end of the 5' UTR; the 3' end of the 5' UTR is linked to the 5' end of the Kozak sequence; the 3' end of the Kozak sequence is linked to the 3' end of the ubiquitinated monomer; the 3' end of the ubiquitinated monomer is linked to the 5' end of the first linker; the 3' end of the first linker is linked to the 5' end of the E protein fragment; the 3' end of the E protein fragment is linked to the 5' end of the second linker; the 3' end of the second linker is linked to the 5' end of the third linker; the 3' end of the third linker is linked to the 5' end of NS3; the 3' end of the NS3 protein fragment is linked to the 5' end of the fourth linker; the 3' end of the fourth linker is linked to the 5' end of the fifth linker; the 3' end of the fifth linker is linked to the 5' end of the NS5 protein fragment; the 3' end of the NS5 protein fragment is linked to the 5' end of the sixth linker; and the 3' end of the sixth linker is linked to the V5... The 5' end of the tag is connected, the 3' end of the V5 tag is connected to the 5' end of the 3'UTR, and the 3' end of the 3'UTR is connected to the 5' end of the polyA tail.
[0117] According to an embodiment of this application, the linking sequence of the first nucleic acid fragment is as follows: the 3' end of the T7 promoter is linked to the 5' end of the 5'UTR; the 3' end of the 5'UTR is linked to the 5' end of the Kozak sequence; the 3' end of the Kozak sequence is linked to the 5' end of the EDIII protein fragment; the 3' end of the EDIII protein fragment is linked to the 5' end of the C3d protein fragment; the 3' end of the C3d protein fragment is linked to the 5' end of the His tag; the 3' end of the His tag is linked to the 5' end of the 3'UTR; and the 3' end of the 3'UTR is linked to the 5' end of the polyA tail.
[0118] According to embodiments of this application, the EDIII protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 1.
[0119] According to embodiments of this application, the C3d protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 2.
[0120] According to embodiments of this application, the E protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 3.
[0121] According to embodiments of this application, the NS3 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 4.
[0122] According to embodiments of this application, the NS5 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 5.
[0123] According to an embodiment of this application, the first nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 6.
[0124] According to an embodiment of this application, the second nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 7.
[0125] expression carrier In another aspect, this application proposes an expression vector. According to an embodiment of this application, the expression vector carries the aforementioned nucleic acid molecule. When linking the nucleic acid molecule to the expression vector, the nucleic acid molecule can be directly or indirectly connected to control elements on the expression vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can be directly derived from the expression vector itself, or they can be exogenous, i.e., not derived from the expression vector itself. Naturally, the nucleic acid molecule and the control elements only need to be operably linked.
[0126] In this article, "operable ligation" refers to ligating a foreign gene into a vector so that the control elements within the expression vector, such as transcriptional and translational control sequences, can perform their intended functions of regulating the transcription and translation of the foreign gene. Commonly used expression vectors include plasmids and bacteriophages.
[0127] According to embodiments of this application, the expression vector may refer to a cloning vector, which can be obtained by operatively ligating the nucleic acid molecule to a commercially available vector (such as a plasmid). The vector used in this application is not particularly limited; commonly used plasmids such as pSeTag2, PEE14, and pMH3 can be used.
[0128] In some optional embodiments of this application, the expression vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus, or a bacteriophage.
[0129] In some optional embodiments of this application, the expression vector is selected from prokaryotic expression vectors or eukaryotic expression vectors.
[0130] According to embodiments of this application, the expression vector is a non-viral vector or a viral vector.
[0131] vaccine In another aspect of this application, a vaccine is proposed. According to embodiments of this application, the vaccine comprises the aforementioned polypeptide, the aforementioned linear mRNA, the aforementioned nucleic acid molecule, and the aforementioned expression vector. The vaccine according to embodiments of the present invention can efficiently activate animal cell-mediated immune responses. Furthermore, the vaccine contains only protein fragments capable of activating cellular immune responses, avoiding toxic side effects and exhibiting higher safety.
[0132] It should be explained that this application recombines the ZIKV protein by expressing ubiquitinated monomers (Ub) to generate CTLs without producing antibodies that mediate ADE. This design of tandemly expressing multiple antigenic peptides is expected to result in rapid degradation in the proteasome. Flow cytometry results from this application show that the content of tandem proteins in cells transfected with mRNA expressing tandem antigenic peptides is negligible. In contrast, a large amount of protein expression was observed when using proteasome inhibitors, indicating that Ub tandem proteins are rapidly degraded in the proteasome. Moreover, since the antigenic peptides selected in this application have a homology of more than 50% with DENV2, this application can not only prevent Zika virus infection through T-cell immunization, but also resist DENV2 attack by inducing a strong, highly homologous, specific CTL response. For T-cell immunization vaccines, this application did not detect any neutralizing antibodies against ZIKV, and through DENV2 infection in A129 and AG6 mice, stimulation by ZIKV peptides induced high expression of IFNγ and granzyme B in the spleen of DENV2-infected mice. Furthermore, this application also performed CD8... +In the T-cell passive transfer model, both viral load and body weight were protected, further demonstrating that the tandem antigenic peptide of this application can prevent DENV2 to a certain extent. Furthermore, the recombinant sequence of this application avoids the potentially harmful effects of intact genomic proteins. This is evidenced not only by the absence of cell damage observed during mRNA transfection but also by the lack of inflammatory responses observed during in vivo vaccine safety evaluation, proving that the ubiquitinated tandem antigenic peptide of this application is safe and effective. Moreover, based on this, this application also designs an mRNA vaccine fusion adjuvant strategy, which combines the antigen-coding sequence and the C3d complement activation adjuvant sequence in a single mRNA transcript. To mimic the binding of C3d to the antigen and utilize its adjuvant effect, this application utilizes three C3d complement sequences to bind to the antigen. Furthermore, the addition of C3d has also been shown to enhance the primary immune response against DNA vaccines against influenza, measles, human immunodeficiency virus (HIV), and other viruses. Using the third domain of the ZIKV E protein fragment as the antigen, the two immunizations encoding EDIII-C3d in this application can induce an antibody titer that is 8 times higher than that of mRNA encoding only EDIII, which indicates that the vaccine constructed in this application has a good immunization effect.
[0133] Recombinant cells In another aspect of this application, a recombinant cell is provided. According to embodiments of this application, the recombinant cell carries the aforementioned linear mRNA, the aforementioned nucleic acid molecule, the aforementioned expression vector, or expresses the aforementioned polypeptide. According to embodiments of the present invention, the recombinant cell is used to prepare a nucleic acid vaccine or to express at least one of the EDIII and C3d, E, NS3, and NS5 protein fragments of Zika virus to stimulate an immune response in an animal.
[0134] According to embodiments of this application, the recombinant cells are obtained by introducing the aforementioned vector into cells or a host.
[0135] It should be noted that the recombinant cells in this application are not particularly limited and can be prokaryotic cells, eukaryotic cells, or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces, or Proteus mirabilis, etc. The eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosoma, and Trichoderma; insect cells such as armyworms; plant cells such as tobacco; and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells.
[0136] In one optional embodiment of this application, the recombinant cells are mammalian cells, including Vero cells, BHK cells, CHO cells, NSO cells, or COS cells, but do not include animal germ cells, fertilized eggs, or embryonic stem cells.
[0137] It should be noted that the "suitable conditions" mentioned in this application refer to conditions suitable for the expression of the nucleic acid molecules described in this application. Those skilled in the art will readily understand that suitable conditions for the expression of the nucleic acid molecules include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy cell state, suitable cell density, suitable cell culture environment, and suitable cell culture time. The term "suitable conditions" is not particularly limited, and those skilled in the art can optimize the optimal conditions for the expression of the nucleic acid molecules based on the specific environment of their laboratory.
[0138] Methods for preparing linear mRNA In another aspect of this application, a method for preparing the aforementioned linear mRNA is provided. According to an embodiment of this application, the method includes: mixing a first nucleic acid fragment and a second nucleic acid fragment in a predetermined ratio to obtain the linear mRNA; wherein the first nucleic acid fragment encodes the EDIII protein fragment of Zika virus; the second nucleic acid fragment encodes at least one of the E protein fragment, NS3 protein fragment, and NS5 protein fragment of Zika virus; and the first and second nucleic acid fragments are mRNA. According to an embodiment of this application, this method can be used to prepare linear mRNA for the prevention or treatment of diseases caused by Zika virus.
[0139] According to an embodiment of this application, the method includes: mixing a first nucleic acid fragment and a second nucleic acid fragment in a predetermined ratio to obtain the linear mRNA; wherein the first nucleic acid fragment encodes the Zika virus EDIII protein fragment and 1 to 10 tandemly repeated Zika virus complement C3d protein fragments; the second nucleic acid fragment encodes at least one of the Zika virus E protein fragment, NS3 protein fragment, and NS5 protein fragment; and the first and second nucleic acid fragments are mRNA.
[0140] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(1~50).
[0141] According to an embodiment of this application, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(3~10).
[0142] Methods for constructing Zika virus vaccines In another aspect of this application, a method for constructing a Zika virus vaccine is proposed. According to embodiments of this application, the method includes: introducing the aforementioned linear mRNA, the aforementioned nucleic acid molecule, or the aforementioned expression vector into recipient cells. The Zika virus vaccine constructed according to the method of this embodiment is safe, simple, and highly effective.
[0143] According to embodiments of this application, before introducing the linear mRNA, nucleic acid molecule, or expression vector into recipient cells, the process further includes encapsulating the linear mRNA, nucleic acid molecule, or expression vector using an encapsulation vector.
[0144] According to embodiments of this application, the encapsulation carrier is selected from at least one of liposomes, exosomes, polymer carriers, viral carriers, or nanoparticles.
[0145] According to an embodiment of this application, the encapsulation carrier is a liposome.
[0146] According to a specific embodiment of this application, the encapsulation carrier is an iLAND liposome.
[0147] According to embodiments of this application, the recipient cells are Vero cells, HEK293FT cells, HEK293T cells, BHK cells, and insect cells.
[0148] According to an embodiment of this application, the recipient cell is a Vero cell.
[0149] Composition In another aspect of this application, a composition is provided. According to embodiments of this application, the composition comprises the aforementioned polypeptide, the aforementioned linear mRNA, the aforementioned nucleic acid molecule, or the aforementioned vaccine.
[0150] According to embodiments of this application, the composition further comprises a pharmaceutically acceptable excipient, which includes at least one of liposomes, exosomes, polymeric carriers, viral carriers, or nanoparticles.
[0151] According to embodiments of this application, the excipients include, but are not limited to, one or more pharmaceutically acceptable diluents, stabilizers, or pH adjusters.
[0152] According to embodiments of this application, the composition is an injectable preparation.
[0153] It should be noted that the composition includes combinations that are separate in time and / or space, as long as they can work together to achieve the purpose of this application. For example, the components contained in the composition may be administered to the subject as a whole or separately. When the components contained in the composition are administered to the subject separately, the individual components may be administered to the subject simultaneously or sequentially.
[0154] The compositions of this application contain a safe and effective amount of the active ingredient of this application and pharmaceutically acceptable excipients. Such excipients include (but are not limited to): saline, buffer solutions, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the composition should be matched to the route of administration; the composition of this application is in the form of an injection. It is prepared, for example, using physiological saline or an aqueous solution containing glucose and other excipients by conventional methods. The compositions are preferably manufactured under aseptic conditions.
[0155] The effective amount of the active ingredient described in this application may vary depending on the administration method and the severity of the disease to be treated. A preferred effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). For example, due to the urgency of the treatment condition, several separate doses may be administered daily, or the dose may be reduced proportionally.
[0156] Pharmaceutically acceptable excipients described in this application include (but are not limited to): water, saline, liposomes, lipids, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should be compatible with the route of administration, as is well known to those skilled in the art.
[0157] use In another aspect of this application, the use of the aforementioned linear mRNA, nucleic acid molecule, expression vector, recombinant virus, or polypeptide in the preparation of a medicament for the prevention or treatment of Zika virus infection-related diseases is proposed. According to embodiments of the present invention, medicaments prepared based on the aforementioned nucleic acid molecule, expression vector, recombinant virus, or recombinant cell have high safety and can activate animal cell-mediated immune responses and B cell-mediated humoral immunity in a short time.
[0158] The following will explain the solution of this application with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of this application. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0159] In the embodiments described in this invention, the virus sources are as follows: Dengue virus type 1 (DENV1) isolate 16681; GenBank accession number M84727.1. Dengue virus type 2 New Guinea C strain (NGC strain, GenBank accession number: KM204118.1). Dengue virus type 3 YN02 strain (GenBank accession number: KF824903). Dengue virus type 4 GZB5 strain (GenBank accession number: AF289029).
[0160] Example 1: In this embodiment, three tandemly repeated molecular adjuvants C3d are integrated into the ZIKV EDIII gene fragment to form the first rearranged nucleic acid fragment, denoted as EDIII. C3d mRNA; To further enhance the immune response, this embodiment tandemly transcribed the ZIKVE, NS3, and NS5 gene fragments to form a rearranged second nucleic acid fragment, denoted as UbA mRNA. This rearrangement may lead to protein structural instability, thereby being targeted and degraded by the proteasome. To preserve the CTL epitope, this embodiment extended the sequence by 30 nucleotides before and after each cleavage site. Furthermore, this embodiment added an ORF of ubiquitinated (Ub) monomers upstream of the second nucleic acid fragment and modified glycine to alanine at residue 76 to enhance the stability of the Ub / E-NS3-NS5 complex (i.e., the protein complex encoded by the second nucleic acid fragment). This design demonstrated that this modification can promote protein degradation in the proteasome. To ensure efficient in vitro transcription, this embodiment added Kozak sequences upstream of both the first and second nucleic acid fragments to optimize translation initiation efficiency. Subsequently, using a T7 promoter-driven in vitro transcription system, the nucleic acid fragment (mRNA sequence) encoding the Zika virus protein, i.e., the mRNA carrying the first and second nucleic acid fragments, denoted as UbA-EDIII, was obtained. C3d The mRNA contains a first nucleic acid fragment and a second nucleic acid fragment with a mass ratio of 0.226. See the structural diagrams of the first and second nucleic acid fragments for details. Figure 1 Finally, in this embodiment, the mRNA vaccine was encapsulated using iLAND lipid nanoparticles (preparation method see "Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia[J].Scienceadvances, 2022, 8(7):eabm1418.DOI:10.1126 / sciadv.abm1418.") developed in the laboratory to improve its stability and delivery efficiency.
[0161] Example 2: This embodiment uses UbA-EDIII obtained through in vitro transcription prepared in Example 1. C3d The mRNA was encapsulated in iLAND lipid nanoparticles, independently developed in our laboratory, and designated LNP-UbA-EDIII. C3d mRNA. LNP-UbA-EDIII C3dmRNA was diluted to 1 mg / mL with PBS and subjected to DLS (dynamic light scattering) experiments. DLS analysis showed that LNP-UbA-EDIII C3d The particle size is approximately 160 nm, and the polydispersity index (PDI) is 0.16, indicating a highly uniform particle size distribution. Further analysis of LNP-UbA-EDIII... C3d The encapsulation efficiency of mRNA reached as high as 85%, significantly reducing the risk of nucleic acid degradation both in vitro and in vivo. This indicates that the system can efficiently encapsulate mRNA; for details, please refer to [link to results]. Figure 2 A.
[0162] Transmission electron microscopy verified LNP-UbA-EDIII C3d The uniformity of mRNA particles, with their regular morphology and consistent size, provides a physical basis for efficient in vivo delivery. See details for further information. Figure 2 B.
[0163] In addition, LNP-UbA-EDIII C3d The mRNA's pKa value is 6.26, which allows it to remain stable under physiological conditions. However, it can be effectively released in acidic environments (such as endosomes), thereby improving delivery efficiency and enhancing cellular uptake. For details, please refer to [link to relevant documentation]. Figure 2 C.
[0164] Example 3: This embodiment will encapsulate EDIII. C3d iLAND, containing mRNA (i.e., carrying the first nucleic acid fragment), was transfected into HEK293T cells, and the cells were collected for Western blotting. The results showed high expression of EDIII antigen in both the cells and their supernatant, indicating that iLAND can efficiently deliver mRNA into the cells and promote its translation into protein. For details, please refer to [link to relevant documentation]. Figure 3 .
[0165] Example 4: In this embodiment, UbA (carrying a second nucleic acid fragment) mRNA was constructed and transfected into HEK293T cells. After transfection, the cells were treated with the proteasome inhibitor MG132 (10 μM) to evaluate the degradation characteristics of the Zika virus protein encoded by the second nucleic acid fragment. To further verify the expression and degradation function of the Zika virus protein encoded by the second nucleic acid fragment, flow cytometry was used to analyze the transfected HEK293T cells. The results showed that the intracellular antigen expression level of cells transfected with UbA mRNA significantly increased after MG132 treatment, indicating that MG132 can effectively inhibit the degradation of the Zika virus protein encoded by the second nucleic acid fragment. For details, please refer to [link to relevant documentation]. Figure 4This result further confirms that the ubiquitinated monomer introduced in the design of the Zika virus protein encoded by the second nucleic acid fragment can effectively promote the degradation of the Zika virus protein in the proteasome, thereby enhancing its MHC presentation efficiency in cells. The use of MG132 further confirms the degradation characteristics of the Zika virus protein encoded by the second nucleic acid fragment, indicating that its degradation process in cells depends on the proteasome pathway.
[0166] Example 5: This example describes in vitro transcription of EDIII. C3d Immunization experiments were conducted using mRNA vaccines and EDIII mRNA vaccines. Six- to eight-week-old female C57BL / 6 mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) were used as the experimental model. The experimental group consisted of EDIII... C3d The mice were divided into three groups: an mRNA vaccine group, an EDIII mRNA vaccine group, and a negative control group (PBS group). All C57BL / 6 mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and dosage for the negative control group were the same as those for the vaccine group, with intramuscular injection as the method of administration. The mRNA vaccine group doses were 1 μg, 5 μg, and 10 μg mRNA per mouse, respectively. To evaluate the immunization effect, serum samples were collected from mice on days 7, 14, and 28 after the initial immunization, and antibody titers were measured. The titers of binding antibodies in the serum of immunized mice were detected by ELISA, and the titers of neutralizing antibodies in the serum of immunized mice were detected by micro-neutralization assay.
[0167] The titer of binding antibodies in the serum of immunized mice was detected by ELISA. Specifically, the full-length ZIKV E protein (amino acid sequence as shown in SEQ ID NO:20) was analyzed. The ELISA plate containing sodium carbonate-sodium bicarbonate buffer (pH 9.6) was diluted to 0.5 μg / mL and 100 μL was added to each well of a 96-well ELISA plate. The plate was incubated overnight at 4°C. The next day, the coating solution was discarded, and the ELISA plate was blocked with 5% BSA prepared with D-PBS and incubated at 37°C for 2 hours. Serum samples collected from mice in each experimental group were serially diluted in 96-well plates, starting at a ratio of 1:200. The diluted solutions were then transferred to ELISA plates, which were incubated at 37°C for 2 hours. The blocking buffer was discarded, and the plates were washed four times with PBST. Next, Goat Anti-Mouse HRP secondary antibody (purchased from Kangwei Century) diluted 1:1000 with blocking buffer was added, and the plates were incubated at 37°C for 1 hour, followed by five washes with PBST. Then, 50 μL of 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added for color development. After 10 minutes, 50 μL of 2M hydrochloric acid was added to stop the reaction. OD was measured using a Bio-Radi Mark microplate reader. 450 Reading value. The endpoint titer is defined as the serum dilution factor corresponding to an absorbance 2-3 times greater than the background value. Antibody titers below the detection limit are defined as half the detection limit.
[0168] The titer of neutralizing antibodies in the serum of immunized mice was detected by a micro-neutralization assay. The specific method was as follows: VERO cells were seeded in 96-well plates one day in advance using DMEM medium (Invitrogen, C11995500BT) containing 1% FBS (Gibco, 10270-106). The next day, when the cells reached approximately 90% confluence, the immunized mouse serum was serially diluted in the 96-well plates using DMEM medium (Invitrogen, C11995500BT) containing 1% FBS (Gibco, 10270-106). (Specifically, starting with a 10-fold dilution, serial dilutions were performed in 3-fold increments, resulting in 10 dilutions). The virus was also diluted to 6 × 10⁶ using DMEM medium containing 1% FBS. 3 FFU / mL; then, 85 μL of each dilution of immunized mouse serum and 85 μL of virus dilution were mixed in a 96-well round-bottom plate and incubated at 37°C for 2 hours. Next, the serum and virus mixture was added to a VERO cell plate with approximately 90% confluence, and after culturing for 2 hours, DMEM containing 2% FBS was added. Cells were cultured at 37°C for 4 days. After 4 days, the cell culture plate was removed, and cytopathic effects were observed to determine the true virus antibody dilution gradient.
[0169] The results of ELISA and micro-neutralization assays showed that, compared to the EDIII mRNA vaccine, EDIII... C3d The mRNA vaccine produced detectable neutralizing and binding antibodies as early as day 7 after primary immunization, indicating its strong immunogenicity. On day 28 after primary immunization, the highest neutralizing antibody titer induced by a 10 μg dose of the EDIII mRNA vaccine was only 800, while that induced by a 5 μg dose of EDIII... C3d The neutralizing antibody titer induced by the mRNA vaccine was significantly higher than that of the 5 μg dose of the EDIII mRNA vaccine, reaching 6400, which is 8 times that of the EDIII mRNA vaccine. This result indicates that EDIII C3d mRNA vaccines have a significant advantage in inducing neutralizing antibody production; see details below. Figure 5 AD.
[0170] Example 6: Given the high identity (50% to 89%) between ZIKV and DENV2 on three H-2Kb-restricted CTL epitopes (E7-15, NS3347-355, and NS518-27), this high identity may trigger immune cross-reactivity. To further evaluate the cross-protective effect of ZIKV and DENV2 antigenic peptide epitopes, this embodiment uses DENV2-NGC (10... 4PFU (DENV2-16681) infected with Infar1 in 4-5 week old infants – / – Ifngr1 – / – and Infar1 at 4-5 weeks old – / – Mouse model (Lazear, Helen Metal. (2016), vol. 19, 5: 720-30.). Infar1 was collected on day 7 post-infection. – / – Ifngr1 – / – and Infar1 – / – Mouse spleen cells were used, and the response of antigen-specific memory T cells was analyzed using intracellular cytokine assay (ICS). See the schematic diagram for the experimental procedure. Figure 6 .
[0171] Example 7: This embodiment verifies the efficacy of three ZIKV-derived peptides (ZIKV-E7-15, ZIKV-NS3347-355, and ZIKV-NS518-27) (all synthesized by Nanjing Genscript Biotech Co., Ltd. based on their sequences) in Infar1 infants aged 4-5 weeks. – / – Ifngr1 – / – Mice (Lazear, Helen Metal. (2016), vol. 19, 5: 720-30.) memory CD8 + The activation effect of T cells.
[0172] The experimental procedure was as follows: Infar1 infants aged 4-5 weeks were... – / – Ifngr1 – / – Mice were divided into 4 groups. The experimental group mice in group 1 were those that received DENV2-NGC (10) in Example 6. 4 PFU (GenBank accession number: KM204118.1) mice were infected with ZIKV-E7-15(E) derivative peptide and then activated. The control group mice were infected with PBS and then activated with ZIKV-E7-15(E) derivative peptide. The experimental group mice in group 2 were those that received DENV2-NGC (10) in Example 6. 4 After infection with PFU, mice were activated by adding ZIKV-NS3347-355 (NS3) derivative peptide. The control group mice were activated by adding ZIKV-NS3347-355 (NS3) derivative peptide after infection with PBS. The experimental group mice in group 3 were those that received DENV2-NGC (10) in Example 6. 4After infection with PFU, mice were activated by adding ZIKV-NS518-27 (NS5) derivative peptide. The control group mice were infected with PBS and then activated by adding ZIKV-NS518-27 (NS5) derivative peptide. The experimental group mice in group 4 were those that received DENV2-NGC (10) in Example 6. 4 After infection with PFU, mice were treated with co-stimulation using ZIKV-E7-15(E) + ZIKV-NS3347-355(NS3) + ZIKV-NS518-27(NS5) derivative peptides. The control group mice were infected with PBS and then treated with co-stimulation using ZIKV-E7-15(E) + ZIKV-NS3347-355(NS3) + ZIKV-NS518-27(NS5) derivative peptides.
[0173] The results showed that, compared to the experimental group in group 4 which was treated with three peptide co-stimulation, the experimental groups in groups 1, 2, and 3, which experienced memory CD8 stimulation from three peptides respectively, had different effects. + The positive rates of IFN-γ production in T cells were 2.69%, 2.27%, and 2.86%, respectively. After co-stimulation treatment, the frequency of IFN-γ production significantly increased to 7.15%. (See attached results for details.) Figure 7 A. In addition, memory CD8 stimulated by three peptides + The positive rates of granzyme B (GZMB) production in T cells were 6.18%, 5.50%, and 5.17%, respectively, increasing to 7.25% after co-stimulation. See details for further information. Figure 7 B. These results indicate that co-stimulation treatment significantly enhances DENV2 memory CD8. + Effector function of T cells.
[0174] Example 8: Experimental group: UbA mRNA vaccine group, EDIII C3d mRNA vaccine group; control group: PBS control group.
[0175] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group, and the injection method was intramuscular injection. The dose of mRNA vaccine group was 5 μg mRNA per mouse. On day 42, spleen cells were collected from the three groups of C57BL / 6 mice, and CD8 cells were isolated. +T cells were transferred to Infar1 via retro-orbital injection (ROI). – / – Ifngr1 – / – In mice (Lazear, Helen Metal. (2016), vol. 19, 5: 720-30.). The following day, Infar1... – / – Ifngr1 – / – Mice were subjected to DENV2-NGC (10 4 Infected patients with PFU (GenBank accession number: KM204118.1) and had blood drawn for 7 consecutive days post-infection to monitor DENV2-NGC viral load and Infar1. – / – Ifngr1 – / – Mice weighed up to 14 days and Infar1 – / – Ifngr1 – / – For mouse survival rates and experimental procedures, please refer to [link / reference]. Figure 8 A.
[0176] The results showed that no viremia was detected on day 1 post-infection, and viremia peaked on day 4. Meanwhile, the UbA mRNA vaccine group and EDIII... C3d The viral load in the blood of the mRNA vaccine group was lower than that in the PBS control group. See details for further information. Figure 8 B.
[0177] On the 5th day after the viremia subsided, Infar1 – / – Ifngr1 – / – Mice began to lose weight, particularly in the UbA mRNA vaccine group and the EDIII group. C3d The mRNA group experienced slower weight loss on days 6, 7, and 8 compared to the PBS control group. See details for further information. Figure 8 CD. This indicates that, through in vitro stimulation and in vivo adoptive transfer, the UbA mRNA vaccine and EDIII designed in this embodiment... C3d mRNA vaccines showed a certain degree of cross-protection against DENV2 infection.
[0178] Example 9: Experimental group: EDIII C3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0179] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of mRNA vaccine group was 5 μg mRNA per mouse. For the experimental flowchart, please refer to [link to flowchart]. Figure 9 A.
[0180] Fourteen days after the initial immunization, this example measured the IgG antibody titer against the ZIKV-E protein, as well as the antibody titers of the IgG1 and IgG2a subclasses. The results showed that, compared to the PBS group, EDIII... C3d mRNA vaccine group and UbA-EDIII C3d The mRNA vaccine groups all induced high levels of binding antibody titers. See details for further information. Figure 9 C.
[0181] Further testing of antibody titers on day 28 revealed a significant increase in IgG binding antibody titers after booster immunization, exceeding 10-fold, compared to the PBS group and EDIII. C3d mRNA vaccine group and UbA-EDIII C3d The mRNA vaccine group induced higher levels of binding antibody titers in all groups. See details for further information. Figure 9 D.
[0182] On day 42, compared to the PBS group, EDIII C3d mRNA vaccine group and UbA-EDIII C3d The titers of binding antibodies induced by the mRNA vaccine group remained at a high level. (See details below.) Figure 9 E.
[0183] EDIII on day 42 C3d mRNA vaccine group and UbA-EDIII C3d The neutralizing antibody titers induced by the mRNA vaccine group decreased compared to day 28, but remained between 1600 and 2048. See details for further information. Figure 9 B.
[0184] Example 10: In addition to serological responses, this embodiment also evaluated B cells (CD19) + GL7 + CD95 + ) and Tfh (CD3) + CD4 + PD1 + CXCR5 + ) reaction.
[0185] Experimental group: EDIIIC3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0186] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same mRNA vaccine design on day 0 and day 14. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of mRNA vaccine group was 5 μg mRNA per mouse. On day 10, the draining lymph nodes of the three groups of mice were collected for flow cytometry experiments.
[0187] The results showed that, compared to the PBS control group, EDIII C3d mRNA vaccine group and UbA-EDIII C3d The number of GC B cells and Tfh cells in the draining lymph nodes of the mRNA vaccine group was significantly increased. (See details...) Figure 10 This result indicates that ZIKV infection or vaccination can induce a robust Th1-like Tfh cell response. In this embodiment, the significant increase in GC B cells and Tfh cells further confirms the dual efficacy of the ZIKV mRNA vaccine in inducing both humoral and cellular immunity.
[0188] Example 11: Experimental group: UbAmRNA vaccine group, EDIII C3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0189] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of mRNA vaccine group was 5 μg mRNA / mice. (The remaining text appears to be incomplete and requires further context.) C3d mRNA, UbA-EDIII C3d Antigen-specific T-cell responses in the spleen and lymph nodes were assessed on day 42 post-mRNA inoculation. Detectable antigen-specific CD4+ ions were induced in both the spleen and lymph nodes 10 days after primary immunization. + and CD8 +For T cell response results, please refer to [link / details]. Figure 11 AD in the text.
[0190] On day 42, this embodiment uses ZIKV-SMGC-1 (10 2 PFU (GenBank accession number: KX266255) was used to stimulate T cells in vitro. This is compared to using UbA mRNA vaccine or EDIII alone. C3d mRNA vaccine, UbA-EDIII C3d ZIKV-specific CD8 in the mRNA vaccine group + T cells can secrete large amounts of IFN-γ, TNF-α, IL-2, and IL-4. See details for further information. Figure 11 AB in the text. Furthermore, the trends observed in the lymph nodes were similar to those in the spleen; see [link to results]. Figure 11 CD8 in the data. These data indicate that, after booster immunization, antigen-specific CD8... + The frequency of T cells increased significantly, especially in the spleen. This phenomenon suggests that enhanced immunity can further boost CD8. + T cell response. UbA-EDIII C3d mRNA vaccines can not only effectively activate humoral immune responses, but also significantly enhance CD8. + T cell-mediated cellular immune responses.
[0191] Example 12: Experimental group: EDIII C3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0192] Immunization of mice: 4-5 week old Infar1 – / – Rat(Lazear, Helen Metal.(2016),vol.19,5:720-30.) The specific experimental procedure is as follows: All Infar1 – / – Mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and dosage for the negative control group were the same as those for the vaccine group, with intramuscular injection as the method of administration. The mRNA vaccine group received a dose of 5 μg mRNA per mouse. On day 28, blood samples were collected from all three groups of mice and administered via 10... 5 Mice were challenged with PFU containing ZIKV-SMGC-1. Blood samples were then collected for seven consecutive days post-challenge, and body weight changes were recorded until day 14 post-challenge. See the schematic diagram of the experimental procedure below. Figure 12 A.
[0193] The results show that in Infar1– / – In mice, antibodies against UbA-EDIII were detected after immunization. C3d The mRNA vaccine produced high titers of neutralizing and binding antibodies, reaching 3200 and 6400 respectively. See details for further information. Figure 12 B. Following challenge, the PBS control group reached peak viremia on day three, followed by a gradual decline in viral load. In contrast, the UbA-EDIII... C3d mRNA vaccines and EDIII C3d The viral load in the blood of the mRNA vaccine group was consistently lower than that of the PBS group, and UbA-EDIII C3d The viremia level in the group was significantly lower than that in EDIII. C3d For group results, please refer to [link / reference]. Figure 12 D. This indicates that UbA-EDIII C3d mRNA vaccines are more effective at inhibiting viral replication.
[0194] Meanwhile, the PBS group began to experience significant weight loss on day three after challenge, and deaths occurred on day six. By day ten, all mice in the PBS group had died from infection. In contrast, UbA-EDIII... C3d mRNA vaccine group and EDIII C3d Mice in the mRNA vaccine group showed good performance in terms of body weight and survival rate. (See details below.) Figure 12 C, E. Especially in UbA-EDIII C3d In the mRNA vaccine group, mice experienced the least weight loss and no deaths occurred throughout the observation period, demonstrating a stronger protective effect.
[0195] Example 13: Experimental group: EDIII C3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0196] Immunization of mice: 4-5 week old Infar1 – / – Rat(Lazear, Helen Metal.(2016),vol.19,5:720-30.) The specific experimental procedure is as follows: All Infar1 – / – Mice were administered ZIKV-SMGC-1 (10) on day 28. 2 PFU (GenBank accession number: KX266255) virus infection, the virus infection of negative control mice was the same as that of the vaccine group. On day 7 after virus infection, the mice were dissected and the viral load of each tissue was detected.
[0197] The results showed that the viral load in the liver, lungs, kidneys, brain, spleen, testes, and heart tissues of mice in the PBS group was high, similar to the condition of viremia, while EDIII C3d mRNA vaccine group, UbA-EDIII C3d The viral load in the mRNA vaccine group was significantly lower than that in the PBS group, and the difference was statistically significant. See details for further information. Figure 13 AB. Among them, UbA-EDIII C3d The mRNA vaccine group had a low viral load, demonstrating good protective efficacy.
[0198] Furthermore, this embodiment also detected memory neutralizing antibody responses using a ZIKV-SMGC-1 evovirus neutralizing antibody titer assay. In the PBS group mice, the neutralizing antibody titer increased more than fourfold after challenge compared to the initial titer, while UbA-EDIII... C3d The neutralizing antibody titers in the mRNA vaccine group mice remained stable without significant changes. See details for further information. Figure 13 C. This indicates that UbA-EDIII C3d Neutralizing antibodies induced by mRNA vaccines can maintain stable levels after infection.
[0199] Example 14: Experimental group: EDIII C3d mRNA vaccine group, UbA-EDIII C3d mRNA vaccine group; control group: PBS control group.
[0200] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same mRNA vaccine design on days 0 and 14. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of mRNA vaccine group was 5 μg mRNA per mouse. On day 28 after the initial immunization of C57BL / 6 mice, serum was detected by ELISA. The specific experimental method of ELISA was the same as in Example 5, except that the full-length E protein of ZIKV was replaced with the full-length E protein of DENV-2, DENV-3, and DENV-4 (all purchased from Sinocare), and the ELISA coating solution was diluted to 0.5 μg / mL.
[0201] The results showed that EDIII C3d mRNA vaccines and UbA-EDIII C3dThe binding affinity of the mRNA vaccine-induced antibody to DENV2-4 was significantly lower than that of the known ADE antibody Z5. For details, please refer to [link to results]. Figure 14 AD. Furthermore, this embodiment also included validation experiments in K562 cells. Compared to the Z5 antibody, EDIII C3d mRNA vaccines and UbA-EDIII C3d Antibodies induced by mRNA vaccines do not increase the intracellular infectivity of DENV2-4 virus; see details below. Figure 14 EH. These results indicate that EDIII-based mRNA vaccine design can effectively avoid the ADE effect while maintaining neutralizing activity against ZIKV.
[0202] Example 15: Experimental groups: UbA mRNA vaccine group encapsulated with iLAND nanoparticles, and EDIII vaccine group encapsulated with iLAND nanoparticles. C3d mRNA vaccine group, using UbA-EDIII encapsulated with iLAND nanoparticles C3d mRNA vaccine group; control group: PBS control group encapsulated with iLAND nanoparticles.
[0203] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same iLAND-mRNA vaccine design on day 0. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of iLAND-mRNA vaccine group was 5 μg mRNA / mouse. 24 hours after immunization, this example monitored multiple physiological indicators of the mice, including body weight (body weight was monitored until day 30 during booster immunization), body temperature, and the specific gravity of various tissues and organs after dissection.
[0204] The results showed that mice in the experimental group did not experience weight loss or changes in body temperature after immunization with the mRNA vaccine, indicating that mRNA vaccination did not cause significant systemic adverse reactions. (See details...) Figure 15 A. Furthermore, compared with the PBS control group, no significant differences were observed in the spleen-to-body ratio, liver-to-body ratio, spleen-to-brain ratio, liver-to-brain ratio, or individual tissues and organs in the experimental group mice. See details... Figure 15 BD indicates that mRNA vaccination did not cause significant organ enlargement or other abnormalities.
[0205] Example 16: Experimental groups: UbA mRNA vaccine group encapsulated with iLAND nanoparticles, and EDIII vaccine group encapsulated with iLAND nanoparticles.C3d mRNA vaccine group, using UbA-EDIII encapsulated with iLAND nanoparticles C3d mRNA vaccine group; control group: PBS control group encapsulated with iLAND nanoparticles.
[0206] Immunization of mice: 6-8 week old female C57BL / 6 strain mice (from Beijing VitalRiver Laboratory Animal Technology Co., Ltd.) The specific experimental procedure is as follows: All C57BL / 6 mice were immunized with the same iLAND-mRNA vaccine design on day 0. The immunization procedure and injection dosage of the negative control group mice were the same as those of the vaccine group. The injection method was intramuscular injection. The dose of iLAND-mRNA vaccine group was 5 μg iLAND-mRNA / mouse. Twenty-four hours after immunization, the serum biochemical parameters of the mice were monitored to assess the function of the heart, liver and kidneys.
[0207] The results showed that all indicators in both the experimental and control groups were within the normal range, and there were no significant differences between the two groups. For details, please refer to [link to results]. Figure 16 AB. Finally, serum biochemical parameters and histopathological changes were examined. In this embodiment, histopathological examinations were performed on various tissues of mice (including the heart, liver, spleen, and kidneys). No significant pathological changes were found between the experimental and control groups; for details, please refer to [link to relevant documentation]. Figure 16 C. These results indicate that the iLAND-mRNA vaccine is well-tolerated in vivo and did not cause significant tissue damage or inflammatory response.
[0208] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0209] Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of this application.
Claims
1. A polypeptide, characterized in that, a first polypeptide fragment comprising an EDIII protein fragment of Zika virus and optionally 1-10 tandem repeats of a C3d protein fragment of Zika virus complement; a second polypeptide fragment comprising at least one of an E protein fragment, an NS3 protein fragment and an NS5 protein fragment of Zika virus; the first polypeptide fragment and the second polypeptide fragment are linked or not linked.
2. The polypeptide of claim 1, wherein the second polypeptide fragment further comprises a ubiquitination monomer fragment; optionally, the ubiquitination monomer fragment has a mutation of G76A; optionally, the number of the C3d protein fragments is 1-5; optionally, the C-terminus of the EDIII protein fragment is linked to the N-terminus of a first C3d protein fragment, the C-terminus of the first C3d protein fragment is linked to the N-terminus of a second C3d protein fragment, and the C-terminus of the second C3d protein fragment is linked to the N-terminus of a third C3d protein fragment; optionally, the C-terminus of the ubiquitination monomer fragment is linked to the N-terminus of the E protein fragment, the C-terminus of the E protein fragment is linked to the N-terminus of the NS3 protein fragment, and the C-terminus of the NS3 protein fragment is linked to the N-terminus of the NS5 protein fragment; optionally, the second polypeptide fragment further comprises a linker peptide; optionally, the linker peptide comprises a first linker peptide, a second linker peptide, a third linker peptide, a fourth linker peptide, a fifth linker peptide and a sixth linker peptide; optionally, the first linker peptide is disposed between the ubiquitination monomer fragment and the E protein fragment, the second linker peptide and the third linker peptide are disposed between the E protein fragment and the NS3 protein fragment, and the fourth linker peptide and the fifth linker peptide are disposed between the NS3 protein fragment and the NS5 protein fragment; optionally, the C-terminus of the ubiquitination monomer fragment is linked to the N-terminus of the first linker peptide, the C-terminus of the first linker peptide is linked to the N-terminus of the E protein fragment, the C-terminus of the E protein fragment is linked to the N-terminus of the second linker peptide, the C-terminus of the second linker peptide is linked to the N-terminus of the third linker peptide, the C-terminus of the third linker peptide is linked to the N-terminus of the NS3 protein fragment, the C-terminus of the NS3 protein fragment is linked to the N-terminus of the fourth linker peptide, the C-terminus of the fourth linker peptide is linked to the N-terminus of the fifth linker peptide, and the C-terminus of the fifth linker peptide is linked to the N-terminus of the NS5 protein fragment.
3. A linear mRNA, characterized in that comprises: a nucleic acid fragment encoding the polypeptide of claim 1 or 2, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encoding an EDIII protein fragment of Zika virus and optionally 1-10 tandem repeats of a C3d protein fragment of Zika virus complement; the second nucleic acid fragment encoding at least one of an E protein fragment, an NS3 protein fragment and an NS5 protein fragment of Zika virus; the first nucleic acid fragment and the second nucleic acid fragment are linked by a sequence encoding a linker, or are located in different linear mRNA molecules, respectively.
4. An isolated nucleic acid molecule, comprising, the isolated nucleic acid molecule encoding the polypeptide of claim 1 or 2, the nucleic acid molecule being mRNA; Optionally, the isolated nucleic acid molecule includes: a first nucleic acid fragment encoding a Zika virus EDIII protein fragment and, optionally, 1 to 10 tandem repeats of a Zika virus complement C3d protein fragment; The second nucleic acid fragment encodes at least one of the Zika virus's E protein fragment, NS3 protein fragment, and NS5 protein fragment; The first and second nucleic acid fragments are linked by sequences encoding linkers, or are located in different mRNA molecules.
5. The linear mRNA of claim 3 or the nucleic acid molecule of claim 4, wherein, The first nucleic acid fragment and the second nucleic acid fragment are located in different mRNA molecules; Optionally, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(1~50); Preferably, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(3~10).
6. The linear mRNA according to claim 3 or the nucleic acid molecule according to claim 4, characterized in that, The second nucleic acid fragment further includes at least one of encoding the T7 promoter, 5'UTR, Kozak sequence, ubiquitinated monomer, linker, V5 tag, 3'UTR and polyA tail; Optionally, the first nucleic acid fragment further includes at least one of encoding the T7 promoter, 5'UTR, Kozak sequence, His tag, 3'UTR, and polyA tail; Optionally, the linker is 25 to 35 nucleotides in length; Optionally, the connector includes a first connector, a second connector, a third connector, a fourth connector, a fifth connector, and a sixth connector; Optionally, the 3' end of the T7 promoter is connected to the 5' end of the 5' UTR, the 3' end of the 5' UTR is connected to the 5' end of the Kozak sequence, the 3' end of the Kozak sequence is connected to the 3' end of the ubiquitinated monomer, the 3' end of the ubiquitinated monomer is connected to the 5' end of the first linker, the 3' end of the first linker is connected to the 5' end of the E protein, the 3' end of the E protein is connected to the 5' end of the second linker, the 3' end of the second linker is connected to the 5' end of the third linker, the 3' end of the third linker is connected to the 5' end of NS3, the 3' end of the NS3 protein fragment is connected to the 5' end of the fourth linker, the 3' end of the fourth linker is connected to the 5' end of the fifth linker, the 3' end of the fifth linker is connected to the 5' end of the NS5 protein fragment, the 3' end of the NS5 protein fragment is connected to the 5' end of the sixth linker; the 3' end of the sixth linker is connected to the 5' end of the V5 tag, and the V5 The 3' end of the tag is connected to the 5' end of the 3'UTR, and the 3' end of the 3'UTR is connected to the 5' end of the polyA tail. Optionally, the 3' end of the T7 promoter is connected to the 5' end of the 5' UTR, the 3' end of the 5' UTR is connected to the 5' end of the Kozak sequence, the 3' end of the Kozak sequence is connected to the 5' end of the EDIII protein fragment, the 3' end of the EDIII protein fragment is connected to the 5' end of the C3d protein fragment, the 3' end of the C3d protein fragment is connected to the 5' end of the His tag, the 3' end of the His tag is connected to the 5' end of the 3' UTR, and the 3' end of the 3' UTR is connected to the 5' end of the polyA tail.
7. The linear mRNA according to claim 3 or the nucleic acid molecule according to claim 4, characterized in that, The EDIII protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 1; Optionally, the C3d protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 2; Optionally, the E protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 3; Optionally, the NS3 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 4; Optionally, the NS5 protein fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 5; Optionally, the first nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO: 6; Optionally, the second nucleic acid fragment has a nucleotide sequence that is identical to or has at least 90% identity with the nucleotide sequence shown in SEQ ID NO:
7.
8. An expression vector, characterized by, Carrying the nucleic acid molecule as described in any one of claims 4 to 7.
9. The expression vector of claim 8, wherein, The expression vector is a non-viral vector.
10. A vaccine comprising a polynucleotide of claim 1. include: The polypeptide of claim 1 or 2, the linear mRNA of any one of claims 3, 5 to 7, the nucleic acid molecule of any one of claims 4 to 7, or the expression vector of any one of claims 8 to 9.
11. A recombinant cell, wherein, It carries the linear mRNA according to any one of claims 3, 5 to 7, the nucleic acid molecule according to any one of claims 4 to 7, the expression vector according to any one of claims 8 to 9, or expresses the polypeptide according to claim 1 or 2.
12. A method of preparing the linear mRNA according to any one of claims 3, 5-7, characterized in that, include: The first nucleic acid fragment and the second nucleic acid fragment are mixed in a predetermined ratio to obtain the linear mRNA; Wherein, the first nucleic acid fragment encodes the Zika virus EDIII protein fragment and optionally 1 to 10 tandem repeats of the Zika virus complement C3d protein fragment; The second nucleic acid fragment encodes at least one of the Zika virus's E protein fragment, NS3 protein fragment, and NS5 protein fragment; The first and second nucleic acid fragments are mRNA.
13. The method of claim 12, wherein, The mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(1~50); Preferably, the mass ratio of the first nucleic acid fragment to the second nucleic acid fragment is 1:(3~10).
14. A method of constructing a Zika virus vaccine, characterized by, include: The linear mRNA according to any one of claims 3, 5 to 7, the nucleic acid molecule according to any one of claims 4 to 7, or the expression vector according to any one of claims 8 to 9 is introduced into recipient cells.
15. The method of claim 14, wherein, Before being introduced into recipient cells, the process further includes encapsulating the linear mRNA, nucleic acid molecule, or expression vector using an encapsulation vector. Optionally, the encapsulation carrier is selected from at least one of liposomes, exosomes, polymer carriers, viral carriers, or nanoparticles; Preferably, the encapsulation carrier is a liposome.
16. The method of claim 15, wherein, The recipient cells are Vero cells, HEK293FT cells, HEK293T cells, BHK cells, and insect cells; Preferably, the recipient cell is a Vero cell.
17. A composition characterized in that, include: The polypeptide of claim 1 or 2, the linear mRNA of any one of claims 3, 5 to 7, the nucleic acid molecule of any one of claims 4 to 7, or the vaccine of claim 10, and optionally pharmaceutically acceptable excipients.
18. Use of the polypeptide of claim 1 or 2, the linear mRNA of any one of claims 3, 5 to 7, the nucleic acid molecule of any one of claims 4 to 7, the expression vector of any one of claims 8 to 9, the vaccine of claim 10, or the composition of claim 17 in the preparation of a medicament for the prevention or treatment of Zika virus infection-related diseases.
Citation Information
Patent Citations
GABA B receptors
GB2357768A
Lepidopteran GABA-gated chloride channels
WO1998049185A1
Methods and reagents for modulating cholesterol levels
WO2000055318A2
Regulation with binding cassette transporter protein abc1
WO2000078972A2
